SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Exelixis, Inc. (EXEL)
EXEL 46.52-0.2%Dec 24 12:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tejek who wrote (905)3/26/2014 2:33:41 PM
From: DewDiligence_on_SI  Read Replies (1) of 930
 
now we know why it was only a 17 cent gain.
Formal EU approval is a fait accompli (with a 2-3 month lag) once the CHMP has recommended approval of a drug. So yesterday’s PR should not have had more than a puny effect on the share price.

Today's PR is a different story, of course.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News